DexCom, Inc. (NASDAQ:DXCM) is one of the 10 best healthcare equipment stocks to buy according to hedge funds. On February 13, William Plovanic from Canaccord Genuity reduced the price target on DexCom ...

Dexcom is already working on its G8 sensor for continuous glucose monitoring (CGM). But before you get too excited, the product is still a couple of years out, CEO Jake Leach told MD+DI during the J.P ...

People with Type 1 diabetes are estimated to make up to 180 more decisions a day than someone without the disease, according to a study from Stanford University. Each meal, workout, or night’s sleep ...

Investing.com - UBS maintained its Buy rating and $106.00 price target on DexCom (NASDAQ:DXCM) following a Friday sell-off triggered by concerns about the company’s G7 continuous glucose monitoring ...

ARLINGTON, VA / ACCESS Newswire / August 13, 2025 / FriskaAi announced today an agreement with DexCom, Inc., the global leader in glucose biosensing, to integrate data from Dexcom G7 and Dexcom G6 ...

DexCom has a well-established record of introducing the most precise sensors for use in its continuous glucose monitors. On the strength of its technology, DexCom has captured an impressive slice of ...

DexCom DXCM is facing regulatory scrutiny following a warning letter recently posted by the FDA. This could affect the approval of the company’s upcoming 15-day G7 continuous glucose monitor (CGM).

A screenshot from an urgent field safety notice of a diagram showing the Dexcom G6 receiver. Dexcom (Nasdaq:DXCM) recently issued an urgent field safety notice in Europe warning of a potential issue ...

An interdisciplinary team of researchers from various Chinese universities have developed a miniature-sized continuous glucose monitoring system that works as effectively as market-leading systems.

DexCom received FDA approval for its continuous glucose monitoring product, Stelo, to be available over the counter, making it the first OTC CGM product ever. The company has demonstrated robust ...